 |
| |
| Jun-27-19 | Downgrade |
SVB Leerink |
Outperform → Mkt Perform |
|
|
| May-06-19 | Initiated |
SVB Leerink |
Outperform |
$13 |
|
| Mar-28-18 | Resumed |
Leerink Partners |
Outperform |
$52 |
|
| Feb-09-18 | Initiated |
Guggenheim |
Buy |
$53 |
|
| Jun-16-17 | Initiated |
Cantor Fitzgerald |
Overweight |
$50 |
|
| Nov-29-16 | Initiated |
Leerink Partners |
Outperform |
$54 |
|
| Sep-30-16 | Initiated |
JMP Securities |
Mkt Outperform |
|
|
| Jun-10-16 | Initiated |
Guggenheim |
Buy |
$35 |
|
| Nov-02-15 | Initiated |
Jefferies |
Buy |
$20 |
|
| Nov-02-15 | Initiated |
Citigroup |
Buy |
|
|
|
|
| Jul-18-19 09:16AM | Aclaris Therapeutics Enters Oversold Territory Zacks |
| Jul-16-19 01:25PM | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| Jul-10-19 11:35AM | Bronstein, Gewirtz & Grossman, LLC Announces Investigation of (ACRS) Aclaris Therapeutics, Inc. ACCESSWIRE |
| Jul-09-19 12:15PM | ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire +9.07% |
| 10:33AM | Aclaris Shares Trade Higher On Patent Win For Facial Redness Drug Benzinga |
| 09:00AM | What Makes Aclaris (ACRS) a New Buy Stock Zacks |
| 07:00AM | Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% GlobeNewswire |
| Jul-07-19 09:30PM | Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Pintec, Sealed Air, and Aclaris Therapeutics on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire |
| Jul-05-19 03:59PM | Heres What Hedge Funds Think About Aclaris Therapeutics, Inc. (ACRS) Insider Monkey |
| Jul-03-19 04:01PM | Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors GlobeNewswire +5.56% |
| Jul-02-19 11:38AM | ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| Jun-30-19 08:21AM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE |
| Jun-28-19 06:45PM | INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 03:40PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire |
| Jun-27-19 08:00PM | SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -52.13% |
| 01:09PM | Here's Why Aclaris Therapeutics Stock Collapsed Today Motley Fool |
| Jun-26-19 09:30PM | Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Aclaris Therapeutics, electroCore, Pintec, and Sealed Air on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire |
| 08:30PM | Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) Business Wire |
| 05:54PM | INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) Business Wire |
| 04:55PM | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 04:01PM | Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints GlobeNewswire |
| 10:45AM | FDA asks Chester County biopharm company to pull promotional video American City Business Journals |
| Jun-25-19 01:11PM | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| Jun-24-19 05:40PM | Glancy Prongay & Murray LLP Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) Business Wire |
| 02:53PM | INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire |
| 12:02PM | INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) Business Wire |
| 10:06AM | Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aclaris Therapeutics, Inc. (ACRS) ACCESSWIRE |
| Jun-21-19 08:59PM | INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire -9.02% |
| 05:40PM | ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Aclaris Therapeutics, Inc. - ACRS Business Wire |
| 04:29PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS GlobeNewswire |
| Jun-17-19 01:16PM | Help may be on the way, via this Malvern biopharm firm, for male/female pattern baldness American City Business Journals |
| 08:42AM | Aclaris Announces Positive Results From Alopecia Treatment Trial Benzinga |
| 06:00AM | Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness) GlobeNewswire |
| Jun-14-19 04:01PM | Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference GlobeNewswire |
| Jun-07-19 10:41PM | Edited Transcript of ACRS earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents +5.33% |
| May-24-19 07:00AM | Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference GlobeNewswire |
| May-17-19 09:05AM | Rigel Initiates Enrollment in Pivotal Blood Disorder Study Zacks |
| May-16-19 01:09PM | Aclaris Therapeutics, Inc. (ACRS) Q1 2019 Earnings Call Transcript Motley Fool |
| May-08-19 06:55PM | Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates Zacks |
| 05:46PM | Aclaris: 1Q Earnings Snapshot Associated Press |
| 04:01PM | Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire |
| May-07-19 03:03PM | How Do Analysts See Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Performing In The Years Ahead? Simply Wall St. |
| May-01-19 07:00AM | Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire |
| Apr-25-19 07:00AM | Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis GlobeNewswire +6.89% |
| Apr-24-19 07:00AM | Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata GlobeNewswire |
| Apr-05-19 03:04PM | Consider These 3 Falling Knives GuruFocus.com |
| Apr-03-19 10:47AM | Edited Transcript of ACRS earnings conference call or presentation 18-Mar-19 12:00pm GMT Thomson Reuters StreetEvents |
| Mar-27-19 07:00AM | Aclaris Therapeutics to Attend Upcoming Investor Conference GlobeNewswire |
| Mar-18-19 01:15PM | Aclaris Therapeutics, Inc. (ACRS) Q4 2018 Earnings Conference Call Transcript Motley Fool +20.43% |
| 07:34AM | Aclaris: 4Q Earnings Snapshot Associated Press |
| 07:00AM | Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire |
| 06:00AM | Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE |
| Mar-08-19 04:01PM | Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019 GlobeNewswire |
| Feb-28-19 07:00AM | Aclaris Therapeutics Receives European Approvals of ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg GlobeNewswire |
| Feb-19-19 07:00AM | Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology GlobeNewswire -7.01% |
| Jan-18-19 12:30PM | Should You Worry About Aclaris Therapeutics, Inc.s (NASDAQ:ACRS) CEO Salary Level? Simply Wall St. |
| Jan-02-19 07:00AM | Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire |
| Dec-23-18 03:52AM | Do Hedge Funds Love Aclaris Therapeutics, Inc. (ACRS)? Insider Monkey |
| Dec-21-18 07:27AM | Aclaris Therapeutics Enters Oversold Territory Zacks |
| Dec-18-18 07:00AM | Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada CNW Group -10.00% |
| Dec-17-18 04:01PM | Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials GlobeNewswire |
| Dec-11-18 03:17PM | Top 6 Performing IPOs of 2015 (ONCE, GBT) Investopedia |
| Dec-03-18 07:00AM | Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan GlobeNewswire |
| Nov-28-18 07:00AM | Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire |
| Nov-27-18 08:31AM | Aclaris Therapeutics (ACRS) Enters Oversold Territory Zacks |
| 07:50AM | Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Nov-18-18 11:51PM | Edited Transcript of ACRS earnings conference call or presentation 6-Nov-18 10:00pm GMT Thomson Reuters StreetEvents |
| Nov-06-18 06:05PM | Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates Zacks |
| 05:01PM | Aclaris: 3Q Earnings Snapshot Associated Press |
| 04:01PM | Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire |
| Nov-02-18 04:01PM | Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire |
| Oct-30-18 10:33AM | Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for Zacks |
| Oct-29-18 04:01PM | Aclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018 GlobeNewswire |
| Oct-23-18 01:27PM | One Thing To Remember About The Aclaris Therapeutics Inc (NASDAQ:ACRS) Share Price Simply Wall St. |
| Oct-22-18 04:01PM | Aclaris Announces Closing of Public Offering of Common Stock GlobeNewswire |
| Oct-19-18 12:53PM | Aclaris plans $92.9M public stock offering American City Business Journals |
| Oct-17-18 09:44PM | Aclaris Announces Pricing of Public Offering of Common Stock GlobeNewswire |
| 04:01PM | Aclaris Announces Proposed Public Offering of Common Stock GlobeNewswire |
| 08:15AM | The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise Benzinga |
| Oct-16-18 07:27PM | Edited Transcript of ACRS earnings conference call or presentation 15-Oct-18 9:00pm GMT Thomson Reuters StreetEvents -7.08% |
| 11:52AM | $65 million deal: Aclaris buying rights to rosacea drug from Allergan American City Business Journals |
| Oct-15-18 04:01PM | Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan GlobeNewswire |
| Oct-10-18 02:42PM | Consolidated Research: 2018 Summary Expectations for Five Prime Therapeutics, National Health Investors, Starwood Property Trust, Inc., Biohaven Pharmaceutical Holding, Aclaris Therapeutics, and Mitek Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Oct-03-18 07:00AM | Aclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall Clinical Dermatology Conference GlobeNewswire |
| Oct-02-18 07:00AM | Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| Oct-01-18 04:01PM | Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA® (hydrogen peroxide) Topical Solution 40%, (w/w) GlobeNewswire |
| 01:25PM | Aclaris partnership with St. Louis university targets aspiring scientists from underrepresented minority groups American City Business Journals |
| 07:00AM | Aclaris Therapeutics Announces Partnership with Harris-Stowe State University to Support Development of Scientists from Underrepresented Minority Groups GlobeNewswire |
| Sep-24-18 07:00AM | Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts GlobeNewswire |
| Sep-21-18 07:00AM | Aclaris Therapeutics to Attend Upcoming Investor Conferences GlobeNewswire |
| Sep-17-18 07:00AM | Aclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target Meeting GlobeNewswire |
| Sep-05-18 04:01PM | Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| Aug-21-18 07:00AM | Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research GlobeNewswire |
| Aug-16-18 07:40AM | Edited Transcript of ACRS earnings conference call or presentation 3-Aug-18 12:00pm GMT Thomson Reuters StreetEvents |
| Aug-03-18 09:25AM | Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Zacks |
| 07:15AM | Aclaris: 2Q Earnings Snapshot Associated Press |
| 07:00AM | Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments GlobeNewswire |
| 06:00AM | Aclaris Therapeutics, Inc. to Host Earnings Call ACCESSWIRE |
| Aug-02-18 07:00AM | Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| Jul-31-18 08:25AM | Recent Analysis Shows Solar Capital, Aclaris Therapeutics, Fidus Investment, NetApp, RLJ Lodging Trust, and AvalonBay Communities Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
|
|
|
|
| Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Flynn James E | 10% Owner | Jun 27 | Sale | 2.69 | 699,475 | 1,882,077 | 964,101 | Jul 01 05:01 PM | | Flynn James E | 10% Owner | Jun 26 | Sale | 4.50 | 1,704 | 7,671 | 1,072,775 | Jun 26 05:52 PM | | Flynn James E | 10% Owner | Jun 25 | Sale | 4.51 | 51,484 | 232,136 | 1,073,127 | Jun 25 06:31 PM | | Flynn James E | 10% Owner | Jun 24 | Sale | 4.52 | 63,240 | 286,003 | 1,083,761 | Jun 25 06:31 PM | | Flynn James E | 10% Owner | Jun 21 | Sale | 4.62 | 339,537 | 1,567,099 | 1,096,824 | Jun 25 06:31 PM | | Flynn James E | 10% Owner | May 10 | Sale | 6.05 | 180,565 | 1,092,274 | 1,166,959 | May 13 05:24 PM | | Flynn James E | 10% Owner | May 09 | Sale | 6.16 | 434,145 | 2,673,248 | 1,238,828 | May 13 05:24 PM | | Mehra Anand | Director | Oct 22 | Buy | 10.75 | 372,093 | 4,000,000 | 1,911,573 | Oct 23 07:13 PM | | Tullman Stephen A. | Director | Oct 04 | Buy | 14.00 | 7,100 | 99,370 | 177,457 | Oct 05 04:37 PM | | Tullman Stephen A. | Director | Aug 23 | Buy | 15.00 | 6,600 | 98,985 | 170,357 | Aug 27 04:46 PM | | Tullman Stephen A. | Director | Aug 15 | Buy | 15.97 | 6,250 | 99,813 | 163,757 | Aug 17 04:55 PM |
|
|
|
|
|
|
